- Policy
- Certican keeps weighted pricing for now, Samsca lowered 30%
- by Kim, Jung-Ju Sep 24, 2020 06:19am
- Novartis Korea’s immunosuppressant Certican (everolimus) has ultimately dodged the double pricing reduction. Although dismissed from patent litigation and lost from the administrative litigation against the government, the immunosuppressant is to keep its premium pricing benefit as stipulated by the policy that sustains the benefit when the num
- Policy
- Italian-made Gliatirin and Vesseldue-F efficacy questioned
- by Lee, Tak-Sun Sep 23, 2020 06:21am
- A series of drugs from Italian manufacturers are in a tight spot, as they have been selected as an efficacy reevaluation subjects. These drugs do not have sufficient evidence to prove the efficacy, because they hardly have much records of use in countries other than South Korea. The pharmaceutical industry sources reported on Sept. 20, S
- Policy
- Generic companies for Atozet are interested in contractors
- by Lee, Tak-Sun Sep 22, 2020 06:27am
- It is known that generic companies of the hyperlipidemia complex Atozet(Atorvastatin-Ezetimibe, Chong Kun Dang) will sign a consignment contract with Chong Kun Dang today (22nd). Generic companies are paying attention to the number of final contractors and scrutinizing their strengths and weaknesses. According to the industry on the 21st
- Policy
- ORR 100%, Phase III of Lazertinib combination was approved
- by Lee, Tak-Sun Sep 22, 2020 06:26am
- The clinical trial of Lazertinib-Amivantamab, which was released by Janssen at the European Society for Medical Oncology (ESMO) on the 20th, is also being conducted in Korea. As a result of this interim study, the response rate (ORR) was 100%, raising expectations as a treatment for non-small cell lung cancer that threatens Tagrisso. Laz
- Policy
- Goal of generic for Atozet is to be approved in next January
- by Lee, Tak-Sun Sep 22, 2020 06:26am
- Chong Kun Dang's consignment-produced hyperlipidemia combination drug 'Atozet (Atorvastatin-Ezetimibe) is known to have applied for approval this month and is aiming for approval in next January. In that Atozet’s PMS by MDS will expire in next January, it is faster to acquire product approval than generics that have undergone bioequivalen
- Policy
- Acromegaly and Huntington’s disease drugs win approval
- by Lee, Tak-Sun Sep 21, 2020 06:12am
- The South Korean health authority granted licenses for Pfizer Pharmaceutical Korea and Teva Handok, respectively. Pfizer’s acromegaly treatment and Teva Handok’s Huntington’s disease treatment would be now accessible to the patients in need of treatment. The Ministry of Food and Drug Safety (MFDS) granted approval on Somavert (pegvis
- Policy
- Cancer Fund Act is promoted
- by Lee, Jeong-Hwan Sep 21, 2020 06:12am
- A bill is being promoted to strengthen the guarantee of expensive anticancer drugs for cancer patients by establishing a cancer management fund. The goal is to improve the reality that patients are deprived of treatment opportunities due to delays in health insurance payments for innovative treatments such as immune anticancer drugs due t
- Policy
- Certican's drug prices will be cut from the 20th
- by Kim, Jung-Ju Sep 21, 2020 06:12am
- The aftermath of the dismissal of the patent lawsuit for Novartis Korea's immunosuppressant Certican (Everolimus) is also reflected in the lawsuit for insurance benefits between the government and companies. The drug price cuts, which the government tried to enforce last year, were suspended due to lawsuits, resumed after a year. The 7th
- Policy
- Sinopharm COVID-19 vaccine, not considered to be introduced
- by Kim, Jung-Ju Sep 18, 2020 06:29am
- Although China is in the midst of developing COVID-19 treatments and vaccines, the government said that it has no plans to import domestically unless the safety and efficacy of these products are secured. Far from being included in the plan to secure 30 million domestic patients, it means that domestic introduction itself is impossible.
- Policy
- Jeil, started commercialization of JLP-1401
- by Lee, Tak-Sun Sep 17, 2020 06:29am
- Jeil has begun commercializing a high blood pressure-hyperlipidemia three-drug, credit-quantity formulation. It is a formulation that combines Telmisartan-Amlodipine-Rosuvastatin, and is known as a new product of Telmiduo Plus, which Jeil is already launching. The MFDS approved the phase I clinical trial protocol of JLP-1401 submitted b
